Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

Journal of Medical Economics

Volumn 16, Issue 11, 2013, Pages 1290-1299

  Lafeuille, Marie Hélène ^a   Gravel, Jonathan ^a   Lefebvre, Patrick ^a   Fastenau, John ^b   Muser, Erik ^b   Doshi, Dilesh ^b   Duh, Mei Sheng ^c  

^a GROUPE D ANALYSE   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c ANALYSIS GROUP   (United States)

Author keywords

Claims data; Healthcare costs; Relapse episodes; Resource utilization; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

ADULT; AGED; ARTICLE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MORBIDITY; OUTPATIENT; RELAPSE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIPSYCHOTIC AGENTS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84886383563     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.841705     Document Type: Article

References (28)

1. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. APA, 2004. http://psychiatryonline. org/content.aspx?bookid=28§ionid=1665359. Accessed September 10, 2012
2. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLOS Med 2005;2:e141
3. Murray CJ, Lopez AD, eds. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Boston, MA: Harvard School of Public Health, 1996
4. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2004;2:13
5. World Health Organization (WHO). The global burden of disease: 2004 update. Geneva, Switzerland: WHO, 2008
6. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
7. Andreasen NC. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995;346:477-81
8. De Sena EP, Santos-Jesus R, Miranda-Scippa A, et al. Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Revista Brasileira de Psiquiatria 2005;25:220-3
9. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
10. Hong J, Windmeijer F, Novick D, et al. The cost of relapse in patients with schizophrenia in the European SOHO (Schizophrenia Outpatient Health Outcomes) Study. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:835-41
11. Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
12. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-7
13. Falloon I. Relapse: a reappraisal of assessment of outcome in schizophrenia. Schizophr Bull 1984;10:293-9
14. Burns T, Fiander M, Audini B. A Delphi approach to characterising relapse' as used in UK clinical practice. Int J Soc Psychiatry 2000;46:220-30
15. Keks N, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomized, controlled, open-label study. Br J Pharmacol 2007;191:131-9
16. Morken G, Widen J, Grawe R. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 2008;8:32
17. Stargardt T, Weinbrenner S, Busse R, et al. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine Care. J Ment Health Policy Econ 2008;11:89-97
18. Hui CLM. Relapse in schizophrenia. H K Med Diary 2011;16:8-9
19. Masand P, O'Gorman C, Mandel FS. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of Ziprasidone Clinical Study Data. Schizophr Res 2011;126: 174-83
20. Wu EQ, Shi L, Birnbaum H, et al. Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med 2006;36:1535-40
21. Schulman KA, Yabroff KR, Kong J, et al. A claims data approach to defining an episode of care. Health Serv Res 1999;34:603-21
22. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
23. Quan HV, Sundararajan P, Halfon A, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care 2005;43:1130-9
24. Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Newbury Park, CA: Sage Publications, 1993
25. Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
26. Beard SM, Maciver F, Clouth J, et al. A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany. Eur J Health Econ 2006;7:165-72
27. Perkins D, Lieberman J, Gu H, et al; HGDH Research Group. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185: 18-24
28. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000;320:1197-2000